Organovo Shares Soar Following FD Disclosure

Shares of Organovo (NYSE: ONVO) gained more than 12 percent following the company's regulation FD disclosure.

In an 8-K filing on Thursday, Organovo reported positive results from a collaborative study using the company's 3D Human Liver Tissues.

The filing states, "Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented results from a collaborative study executed by Organovo scientists at the Company's San Diego facility. The results of the study showed Organovo's 3D Liver system was able to distinguish a toxic drug known to cause drug induced liver injury (DILI) from a close chemical analogue that is known to be non-toxic. Further, the toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems."

Roth presented his findings and the material at 3D Cell Conference in Germany on June 25, 2014.

Shares of Organovo were last trading at $7.98, up 8.7 percent.